Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-120 in Treatment-Naive Wet AMD (VAPOR1)
NCT02401945Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DE-120 in exudative age-related macular degeneration, sponsored by Santen Pharmaceutical. Started Apr 2015; status: completed.
02
Drugs
DE-120
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT02401945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401945.